MDACC Study No:2011-0509 ( NCT No: NCT01446133)
Title:Combination of Lenalidomide and Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy
Principal Investigator:Alessandra Ferrajoli
Treatment Agent:Lenalidomide; Rituximab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
lenalidomide and rituximab can help to control CLL. The safety of this drug
combination will also be studied.

Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.

Rituximab is designed to attach to cancer cells and damage them, which may
cause the cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase II
Treatment Agents:Lenalidomide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene Corp.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Alessandra Ferrajoli
For Clinical Trial Enrollment:713-792-2063
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults